Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 4, 2026
- Arcus Biosciences expects cash runway into 2029 after $288 million in October equity financing. Third-quarter 2026 revenue was $9 million, net loss was $128 million, and PEAK-20 initiation is expected in the fourth quarter of 2026.
- 10-Q report · filed Nov 4, 2026
- Arcus had $694 million of cash, cash equivalents and marketable securities at September 30, 2026 and raised approximately $288 million in October 2026; together, these are expected to fund planned operations into 2029.
The audio replay and transcript follow the call.